Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC)

557 Background: Little is known about endocrine symptoms, QoL and sexual function in premenopausal women with BC receiving adjuvant endocrine therapy. TEXT and SOFT are the first trials providing p...